NewAmsterdam Pharma Co N.V. (NAMS) Financial Statements
NewAmsterdam Pharma Co N.V. (NAMS) reported trailing twelve-month revenue of $7.1M (down 88.9% year on year) and net income of -$259.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$143.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAMSNewAmsterdam Pharma Co N.V.Follow NAMS — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 14.1 | 45.6 | 22.5 | 7.1 | |
| Research & development | 159.4 | 151.4 | 141.8 | 149.2 | |
| Operating income | -183.0 | -176.3 | -225.7 | -244.4 | |
| Pre-tax income | -176.9 | -241.6 | -203.8 | -259.5 | |
| Income tax | 0.0 | -0.0 | — | — | |
| Net income | -176.9 | -241.6 | -203.8 | -259.5 | |
| Diluted EPS ($) | -2.15 | -2.56 | -1.72 | -2.16 | |
| Diluted shares (mn) | 82.2 | 94.4 | 118.4 | — |
USD millions · SEC XBRL
NewAmsterdam Pharma Co N.V. — questions
- What is NewAmsterdam Pharma Co N.V.'s revenue?
- $7.1M over the twelve months to 2026-06-30, down 88.9% year on year, from its 10-Q and 10-K filings.
- What is NewAmsterdam Pharma Co N.V.'s net income?
- -$259.5M over the twelve months to 2026-06-30.
- What is NewAmsterdam Pharma Co N.V.'s free cash flow?
- -$143.7M over the twelve months to 2026-06-30.
- What are NewAmsterdam Pharma Co N.V.'s diluted earnings per share?
- $-2.16 over the twelve months to 2026-06-30.
Every figure on this page comes from NewAmsterdam Pharma Co N.V.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.